{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:19:02Z","timestamp":1785417542598,"version":"3.56.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Asparaginases are a mainstay treatment for pediatric acute lymphoblastic leukemia (ALL). Recent reports identified hypoglycemia associated with asparaginases. Other reports describe hypoglycemia associated with 6-mercaptopurine (6-MP), another fundamental ALL therapy. Little is known about the risk of hypoglycemia associated with ALL therapy, an adverse event that puts children at risk of decreased level of consciousness, seizures, and possibly negative neurocognitive sequelae.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a retrospective chart review of 6 children with hypoglycemia during ALL treatment in our institution from May 2016 to August 2019. Timing and duration of hypoglycemia relative to polyethylene glycol (PEG)\u2013asparaginase, 6-MP, and corticosteroids were determined. Laboratory values of the critical sample were collected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median age was 2.75 (interquartile range: 1.88 to 3.63) years. Three patients had trisomy 21. The onset of hypoglycemia was 5 to 19 days after the most recent PEG-asparaginase administration or 6 to 7 months after initiating daily 6-MP. Sixteen hypoglycemic events were documented, and 9\/16 had a critical sample drawn. Six events were hypoketotic, associated with PEG-asparaginase. Three were ketotic, associated with 6-MP. Two patients required treatment with diazoxide and cornstarch.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Hypoglycemia associated with PEG-asparaginase occurred later and lasted longer than previous reports with <jats:sc>l<\/jats:sc>-asparaginase, with the likely mechanism being hyperinsulinism. 6-MP was associated with ketotic hypoglycemia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002818","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:15:53Z","timestamp":1709032553000},"page":"e121-e126","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Hypoglycemia Associated With PEG-asparaginase and 6-MP Therapy During Treatment of Acute Lymphoblastic Leukemia in Pediatric Patients: A Case Series"],"prefix":"10.1097","volume":"46","author":[{"given":"Mary R.","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ahmet","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylene","family":"Bassal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Speckert","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Geraghty","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Somerville","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"R2-20250804","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26555","article-title":"Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU","volume":"64","author":"Lebovic","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/pbc.21980","article-title":"Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia","volume":"52","author":"Lowas","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4103\/0253-7613.190762","article-title":"L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha","volume":"48","author":"Panigrahi","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2162-3619-1-8","article-title":"Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report","volume":"1","author":"Tanaka","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1515\/jpem-2014-0227","article-title":"L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient report","volume":"28","author":"Misgar","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clinthera.2020.02.015","article-title":"Successful management of L-asparaginase\u2013associated pancreatitis with octreotide and pegylated asparaginase in 2 patients with acute lymphoblastic leukemia: is there a different rare warning sign of hypoglycemia for L-asparaginase\u2013associated pancreatitis?","volume":"42","author":"K\u00f6ker","year":"2020","journal-title":"Clin Ther"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpeds.2015.03.057","article-title":"Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children","volume":"167","author":"Thornton","year":"2015","journal-title":"J Pediat"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ped.13457","article-title":"Treatment and biology of pediatric acute lymphoblastic leukemia","volume":"60","author":"Kato","year":"2018","journal-title":"Pediatr Int"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1067\/mpd.2001.111273","article-title":"Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia","volume":"138","author":"Halonen","year":"2001","journal-title":"J Pediat"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mpo.10097","article-title":"Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia","volume":"39","author":"Ziino","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MPH.0b013e3182025507","article-title":"Severe hypoglycemic seizures in a child receiving 6-mercaptopurine","volume":"33","author":"El-Bitar","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"226","DOI":"10.6065\/apem.2018.23.4.226","article-title":"Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia","volume":"23","author":"Cho","year":"2018","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1651-2227.2003.tb00466.x","article-title":"Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia","volume":"92","author":"Halonen","year":"2007","journal-title":"Acta Paediatr"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08880018.2020.1713940","article-title":"Severe mercaptopurine-induced hypoglycemia in acute lymphoblastic leukemia","volume":"37","author":"Rebelo","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jpeds.2015.09.045","article-title":"Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children","volume":"168","author":"Ferrara","year":"2016","journal-title":"J Pediat"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1016\/j.bmcl.2007.09.064","article-title":"A simple method for the preparation of PEG-6-mercaptopurine for oral administration","volume":"17","author":"Zacchigna","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"R20-20250804","first-page":"654","article-title":"Management of toxicities associated with pegasparagase in treatment of patients with lymphoid malignancy: experience from 443 cases in a single center","volume":"39","author":"Cong","year":"2018","journal-title":"Chin J Hematol"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.01.002","article-title":"Recent developments in L-asparaginase discovery and its potential as anticancer agent","volume":"100","author":"Shrivastava","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.celrep.2014.09.030","article-title":"Glutamate acts as a key signal linking glucose metabolism to incretin\/cAMP action to amplify insulin secretion","volume":"9","author":"Gheni","year":"2014","journal-title":"Cell Reports"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJM199805073381904","article-title":"Mutations of the glutamate dehydrogenase gene","volume":"338","author":"Stanley","year":"1998","journal-title":"N Engl J Med"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2009-07-235291","article-title":"Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children\u2019s Oncology Group","volume":"116","author":"Maloney","year":"2010","journal-title":"Blood"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pbc.20193","article-title":"Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952","volume":"44","author":"Bassal","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-10-3446","article-title":"Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children\u2019s Cancer Group study","volume":"106","author":"Whitlock","year":"2005","journal-title":"Blood"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/pedi.13333","article-title":"Increased referrals for congenital hyperinsulinism genetic testing in children with trisomy 21 reflects the high burden of non-genetic risk factors in this group","volume":"23","author":"Hewat","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"R29-20250804","first-page":"70","article-title":"Ketotic hypoglycemia in patients with Down syndrome","volume":"62","author":"Drachmann","year":"2021","journal-title":"JIMD Rep"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"e29467","DOI":"10.1002\/pbc.29467","article-title":"Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia","volume":"69","author":"Rosenfeld","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pbc.20089","article-title":"A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children\u2019s Oncology Group)","volume":"43","author":"Bell","year":"2004","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:51Z","timestamp":1754337891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002818","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"2023-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}